96 related articles for article (PubMed ID: 2577382)
1. Immunological differences between squamous cell cancer patients treated with and without biological response modifier (OK-432): evaluation at a period of more than one year after the last treatment.
Yoshimura Y; Oka M; Harada T; Inou Y; Saito H; Odagawa T; Matsumoto K
J Osaka Univ Dent Sch; 1989 Dec; 29():117-22. PubMed ID: 2577382
[TBL] [Abstract][Full Text] [Related]
2. [Changes of peripheral lymphocyte subsets in patients with oral squamous carcinoma].
Moroyama T; Endo K; Hazutani J; Iwao I; Shiratsuki T; Mitsui K; Sugihara K; Okahara Y; Hara J; Sakamoto T
Gan No Rinsho; 1985 Feb; 31(2):117-21. PubMed ID: 3157809
[TBL] [Abstract][Full Text] [Related]
3. Modulation of NK activity in regional lymph nodes by preoperative immunotherapy with OK-432 in patients with cancer of the oral cavity.
Vinzenz K; Matejka M; Watzek G; Porteder H; Neuhold N; Micksche M
Cancer Detect Prev Suppl; 1987; 1():463-75. PubMed ID: 3480060
[TBL] [Abstract][Full Text] [Related]
4. [The effect of OK-432 in the treatment of primary lung cancer].
Kishimoto T; Okada K
Gan To Kagaku Ryoho; 1987 Apr; 14(4):1051-6. PubMed ID: 3494430
[TBL] [Abstract][Full Text] [Related]
5. [The clinical value of long-term administration of OK-432 in head and neck cancer].
Mitarai K; Tsukuda M; Tamamushi N; Mochimastu I; Kubota A; Sawaki S
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 1):945-50. PubMed ID: 3963858
[TBL] [Abstract][Full Text] [Related]
6. [Preoperative immunotherapy in patients with gastric cancer--with special reference to analysis with monoclonal antibodies of T-lymphocyte subsets and interleukin-2 oral administration of OK-432 (Picibanil)].
Izumi M
Nihon Geka Gakkai Zasshi; 1993 Jan; 94(1):27-32. PubMed ID: 8437550
[TBL] [Abstract][Full Text] [Related]
7. [Immunotherapy of terminal-stage malignant tumors with the immunopotentiator OK-432--a comparison between SU-PS test-responder and -nonresponder patients].
Yagi Y; Yagi S; Ichiki H
Gan No Rinsho; 1987 Jun; 33(7):815-21. PubMed ID: 3302349
[TBL] [Abstract][Full Text] [Related]
8. [A double blind study to evaluate the optimal dose and its frequency for oral administration of OK-432 (picibanil) by immunological parameters (the 2nd report)].
Shiraishi T; Nio Y; Imai S; Tsubono M; Morimoto H; Tseng CC; Tobe T; Tanaka T; Kitamura O; Sakanashi S
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):997-1012. PubMed ID: 2202770
[TBL] [Abstract][Full Text] [Related]
9. Effects of biological response modifier on thoracic duct lymphocytes in recurrent gastric cancer. Evaluation of OK-432, a hemolytic streptococcus preparation.
Hanaue H; Kim DY; Kubota M; Kurosawa T; Shikata J; Kondoh Y; Ogoshi K; Makuuchi H; Nakasaki H; Mitomi T
Tokai J Exp Clin Med; 1987 May; 12(2):97-102. PubMed ID: 3502432
[TBL] [Abstract][Full Text] [Related]
10. [Immunotherapy, with OK-432 for cases of nasopharyngeal carcinoma].
Tsukuda M; Tamamushi N; Mochimatsu I; Mitarai K; Kaneko M; Sawaki S
Gan To Kagaku Ryoho; 1986 Jan; 13(1):53-9. PubMed ID: 3942399
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of Su-polysaccharide (Su-PS) skin test in patients with primary lung cancer treated with chemotherapy and administration of OK-432, with special reference to the therapeutic effect and prognosis].
Horiuchi M; Sato K; Nakarai I; Shinoda A
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 2):468-74. PubMed ID: 2181937
[TBL] [Abstract][Full Text] [Related]
12. [Two-color flow cytometry analysis of lymphocyte subsets in patients with acute myocardial infarction and post-myocardial infarction syndrome].
Tsuchihashi M; Sakaguchi Y; Nakamura M; Sutani T; Tsuruta S; Kato S; Uemura S; Nishida Y; Hashimoto T; Kagoshima T
J Cardiol; 1995 Aug; 26(2):69-79. PubMed ID: 7674146
[TBL] [Abstract][Full Text] [Related]
13. Final report of a randomized controlled study with streptococcal preparation OK-432 as a supplementary immunopotentiator for laryngeal cancer.
Kimura T; Suzuki K; Motai H; Miyamoto N; Tsuge I; Ito Y; Baba S
Acta Otolaryngol Suppl; 1996; 525():135-41. PubMed ID: 8908288
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of serum T-lymphocyte subsets and NK cell activity in patients with hypopharyngeal squamous cell carcinoma].
Chen WK; Song M; Chen FJ; Guo ZM; He LR; Yan SL
Ai Zheng; 2006 Oct; 25(10):1300-2. PubMed ID: 17059781
[TBL] [Abstract][Full Text] [Related]
15. [Immunohistochemical research for T cell subsets infiltrating in squamous cell carcinoma of oral cavity by monoclonal antibody].
Lu DH
Zhonghua Kou Qiang Yi Xue Za Zhi; 1992 Jan; 27(1):34-6, 62. PubMed ID: 1499396
[TBL] [Abstract][Full Text] [Related]
16. [Effect of intravenous treatment with OK-432 on the bone marrow in patients with lung cancer].
Fujii M; Ishikawa M; Toki H
Gan No Rinsho; 1984 Mar; 30(3):230-2. PubMed ID: 6325756
[TBL] [Abstract][Full Text] [Related]
17. Differential recovery of circulating T cell subsets after nodal irradiation for Hodgkin's disease.
Haas GS; Halperin E; Doseretz D; Linggood R; Russell PS; Colvin R; Barrett L; Cosimi AB
J Immunol; 1984 Feb; 132(2):1026-30. PubMed ID: 6361130
[TBL] [Abstract][Full Text] [Related]
18. Differential regulation of IL-2 and IL-4 in patients with tobacco-related oral squamous cell carcinoma.
Manchanda P; Sharma SC; Das SN
Oral Dis; 2006 Sep; 12(5):455-62. PubMed ID: 16910915
[TBL] [Abstract][Full Text] [Related]
19. [Sapylin immunotherapy in oral squamous cancer].
Lu CY
Zhonghua Kou Qiang Yi Xue Za Zhi; 1990 Jul; 25(4):213-5, 252. PubMed ID: 2128234
[TBL] [Abstract][Full Text] [Related]
20. [Relation between prognosis and the Su-PS skin reaction in patients with non-resected primary lung cancer receiving OK-432].
Nakarai I; Rikitake H; Koga T; Hayashi A; Harada Y; Takamoto M; Ishibashi T; Shinoda A; Sagawa K
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3050-7. PubMed ID: 2823723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
